Drug Delivery Receptors Status (Oct 2026) Headline weight loss
Foundayo Daily oral, any time GLP-1 FDA-approved Apr 2026 11.2% at 72 weeks
Wegovy pill Daily oral, empty stomach GLP-1 FDA-approved Dec 2025 13.6% at 64 weeks
Zepbound Weekly injection GLP-1 + GIP FDA-approved 2023 ~21% at 72 weeks
A caveat almost every comparison article drops
None of these drugs has been tested head-to-head against Foundayo for weight loss. Every number comes from a separate trial with its own population, length, and placebo group.
The one direct comparison
In type 2 diabetes, ACHIEVE-3 showed orforglipron beat oral semaglutide at the lower 7 and 14 mg doses on both blood sugar and weight. But that’s not a comparison with the 25 mg Wegovy pill.
Conclusion
On published numbers, Foundayo sits slightly below the Wegovy pill and well below the injectables. What it’s selling is convenience, price, and a legal prescription, not the biggest result.